Most schools in the United States do not require the BCG tuberculosis vaccine, and the vast majority of American children never receive it. Instead, states that mandate any TB-related requirement for school entry typically ask for a screening test, not a shot. A 2017 legal analysis found that 29 states plus Washington, D.C., have no TB screening requirements at all for K–12 entry, meaning roughly half the country lets children enroll without any TB documentation whatsoever.1PubMed Central. Gaps in Federal and State Screening of Tuberculosis in the United States The confusion between vaccines and tests runs deep, though, especially for families who immigrated from countries where BCG is given at birth and where a positive skin test is expected, not alarming.
Why the U.S. Does Not Require BCG Vaccination
BCG (Bacille Calmette-Guérin) is one of the most widely used vaccines in the world. Over 80 percent of countries still recommend it for all newborns, and universal BCG programs cover every nation in sub-Saharan Africa, Latin America, and East and South Asia.2BMJ Open. Tracking changes in national BCG vaccination policies and practices using the BCG World Atlas But the United States, along with a handful of other low-burden countries, never adopted universal BCG vaccination. The reasoning is straightforward: BCG is good at preventing the most dangerous forms of childhood TB, particularly TB meningitis and the widespread form called miliary TB, but its protection against the common adult lung form is inconsistent.3The Lancet. Cost-effectiveness of BCG vaccination against severe childhood tuberculosis under different epidemiological scenarios In a country where TB rates are low, the vaccine’s modest and variable protection didn’t justify the trade-off: it muddies the results of the primary screening tool, the tuberculin skin test.
Protection from BCG also fades. A study tracking a Norwegian population found evidence consistent with long-lasting but gradually waning protection over time.4PubMed. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study Research in England estimated that BCG effectiveness dropped steeply after about 15 to 20 years, falling to roughly 25 percent by the 20-to-25-year mark and essentially zero beyond that.5International Journal of Epidemiology. The duration of protection of school-aged BCG vaccination in England: a population-based case–control study Immunological research supports this picture, showing that the immune cells trained by BCG lose their punch with age, which is why some researchers have called for booster doses in high-burden settings.6Scientific Reports. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries For the U.S., with its relatively low TB incidence, the calculus has always been that testing and treating infections early is a better investment than vaccinating everyone.
What Schools Actually Require
TB requirements for school entry in the United States are set at the state level, not by the federal government, and they vary enormously. Some states require a tuberculin skin test or a risk-assessment questionnaire before a child can enroll. Others require nothing. That legal review of all 50 states found that 29 states and D.C. impose no K–12 screening requirements, while 30 states and D.C. have no requirements for daycare entry either.1PubMed Central. Gaps in Federal and State Screening of Tuberculosis in the United States Even among the roughly 20 states that do require something, the specifics differ. Some accept a questionnaire that assesses risk factors (travel history, household contacts, country of origin) and only require a test if a risk factor is present. Others require an actual test result on file.
The American Academy of Pediatrics has recommended targeted testing rather than universal screening since 1996, meaning doctors should use a risk-assessment questionnaire and only order a skin test when at least one risk factor is present.7PubMed Central. Tuberculin skin testing in children The logic is that in a low-prevalence population, testing everyone produces more false positives than true positives, leading to unnecessary anxiety, follow-up chest X-rays, and sometimes unnecessary treatment. This targeted approach is the dominant framework in American pediatric practice today.
The Skin Test Problem for BCG-Vaccinated Children
This is where the confusion gets painful for immigrant families. A child born in, say, Brazil or India almost certainly received BCG at birth. When that child arrives in the U.S. and a school or pediatrician orders a tuberculin skin test (TST), the result may come back positive, not because the child has TB, but because the immune system is reacting to the BCG vaccine.
A meta-analysis of the BCG-skin test interaction found that vaccinated people were roughly twice as likely to test positive as unvaccinated people.8PubMed Central. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements The good news is that timing matters. Among children vaccinated as infants, which is the norm in most universal-BCG countries, only about 1 percent still showed a false-positive skin test when tested 10 or more years after vaccination. But among people vaccinated after their first birthday, the false-positive rate was much higher, over 20 percent even a decade later.9PubMed. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? A separate study also confirmed that BCG vaccination significantly confounded skin test results among contacts being screened for infection.10European Respiratory Journal. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test
There is a useful rule of thumb: when a BCG-vaccinated person shows a skin test induration greater than 15 mm, the reaction is more likely caused by genuine TB infection than by the old vaccine.8PubMed Central. A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements Another study reached a similar conclusion at a 10 mm cutoff, finding that induration above 10 mm in BCG-vaccinated patients was more likely due to actual latent infection than cross-reactivity.11PubMed Central. Determining the Need for Additional Testing With Quantiferon TB Gold in Patients With Positive Tuberculin Skin Tests and a History of BCG Vaccination Still, the ambiguity is a real problem for families who just want to get their child enrolled in school without being flagged for follow-up they may not need.
Blood Tests That Sidestep the BCG Problem
The clearest advance in TB screening for BCG-vaccinated people is the interferon-gamma release assay, or IGRA, a blood draw rather than a skin injection. These tests use antigens that are specific to the TB bacterium and are not found in the BCG vaccine strain. That means a prior BCG shot does not trigger a false positive.12Pediatrics. Interferon-γ Release Assays for Diagnosis of Tuberculosis Infection and Disease in Children Meta-analyses have confirmed that IGRA specificity for TB infection is above 95 percent and is unaffected by BCG vaccination history.13Rev. bras. oftalmol.. The potential of the IGRA (Interferon Gamma Release Assay) test for the diagnosis of ocular tuberculosis
In children specifically, a systematic review and meta-analysis found that IGRAs had a pooled sensitivity of about 85 percent and specificity of about 94 percent for diagnosing active TB. Among children under five, the numbers were similar.14PubMed. Utility of interferon-gamma releasing assay for the diagnosis of active tuberculosis in children: A systematic review and meta-analysis In head-to-head comparisons predicting which people would actually go on to develop TB disease, blood-based IGRAs outperformed the skin test, with roughly 50 to 65 percent better predictive value.15JAMA Network Open. Comparison of Tuberculin Skin Testing and Interferon-γ Release Assays in Predicting Tuberculosis Disease
There is a trade-off. The skin test appears to be somewhat more sensitive than IGRAs in certain settings, particularly among children recently exposed to a known TB case, meaning it catches a few more true infections but also flags more false ones.16PLoS ONE. A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children For practical school-entry purposes, though, the IGRA is often the better choice for a BCG-vaccinated child because it eliminates the vaccine-related ambiguity that sends families down an unnecessary diagnostic rabbit hole.
If your child was vaccinated with BCG abroad and you are facing a school-entry TB screening requirement, ask the pediatrician about an IGRA blood test rather than a skin test. Many clinicians now default to IGRAs for BCG-vaccinated children precisely because the result is easier to interpret.
What Happens After a Positive Test
A positive TB screening test, whether skin or blood, does not mean a child has active tuberculosis. The vast majority of people infected with the TB bacterium enter a latent state: they carry the organism but have no symptoms, no abnormal chest X-ray findings, and cannot spread it to others.17PubMed Central. Tuberculosis Infection and Latent Tuberculosis In evolutionary terms, latency is the norm for this particular bacterium; most of its human hosts never become sick.18PubMed Central. The emergence of latent infection in the early evolution of Mycobacterium tuberculosis
A child who screens positive will usually be sent for a chest X-ray to rule out active disease. If the X-ray is clear and the child has no symptoms (persistent cough, fever, weight loss, night sweats), the diagnosis is latent TB infection. Schools generally allow enrollment once active TB has been ruled out, though some require documentation that the child has started treatment for latent infection.
Treatment for latent TB used to mean nine months of a daily medication called isoniazid, which is effective but hard to finish. A study at a U.S.-based TB clinic found that a shorter regimen of four months of rifampin had significantly higher completion rates: about 84 percent of children finished the shorter course compared with roughly 69 percent on the nine-month isoniazid regimen, with similarly low rates of side effects and no cases progressing to active TB in either group.19The Pediatric Infectious Disease Journal. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic The longer regimen saw more dropouts due to families relocating or simply losing contact with the clinic. The shorter option is now widely recommended for children.
Why Schools Screen at All in a Low-Burden Country
The United States has relatively low TB rates overall, but the disease is not evenly distributed. TB clusters in certain urban areas, immigrant communities, and populations with risk factors like homelessness or immunosuppression. Screening children from higher-risk backgrounds catches latent infections before they have any chance of becoming active and spreading in a school setting.
When school transmission does happen, it can be substantial. An outbreak investigation in a Chinese boarding school found 46 active cases among 258 students and 15 staff members, an attack rate of almost 17 percent. Students in the same class as an infectious case faced a secondary attack rate of about 8 percent, and students with smear-positive TB (the most contagious form) were estimated to be roughly 28 times as infectious as smear-negative cases.20PubMed Central. Transmissibility of tuberculosis among school contacts: an outbreak investigation in a boarding middle school, China A UK retrospective study at an inner-city secondary school found that students in the same school year as an infectious index case had about six times the odds of being diagnosed with active TB compared with students in other year groups.21Eurosurveillance. Risk of developing tuberculosis from a school contact: retrospective cohort study, United Kingdom, 2009 Close classroom contact was the main driver; staff appeared to be at lower risk than students.
Cost-effectiveness analyses paint a mixed picture. Targeted screening of high-risk student populations, rather than testing every child, offers far better value. One Australian study of a targeted school screening program estimated that the cost per case of TB disease avoided was about A$24,000, concluding that targeted school programs are an important tool for TB control in low-burden settings.22PubMed. Tuberculosis, focussed tools and the right schools: estimated impact and cost of a targeted student screening programme for tuberculosis infection By contrast, universal testing strategies are expensive relative to what they catch, costing over $700,000 per additional case prevented compared with targeted approaches.23International Journal of Tuberculosis and Lung Disease. Cost-effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis This economic reality is a big reason why universal school-entry TB testing has not caught on in most U.S. states.
The Burden on Children and Families
The practical hassle of TB screening is real but finite. The larger burden falls on children who actually have TB disease, or whose families are caught in the limbo of follow-up after a positive screen. A scoping review of the socioeconomic impact of TB on children and adolescents found effects ranging from missed schooling and family separation to stigma and impoverishment.24PubMed Central. The socioeconomic impact of tuberculosis on children and adolescents: a scoping review and conceptual framework Children who test positive at school can face social stigma even when they have latent infection that poses no risk to anyone. Parents report anxiety about their child being singled out, delayed enrollment, or having to navigate a health system in a new country while dealing with language barriers.
For families who immigrated from BCG-vaccinating countries, the sequence often unfolds like this: school requires TB test, child gets skin test, skin test is positive (possibly from BCG, possibly from latent infection), school demands follow-up, family must get a chest X-ray and possibly a blood test, and if latent infection is confirmed, the child starts months of medication. The whole process can take weeks to resolve during a time when the family is trying to settle into a new community. Asking for the IGRA upfront, as discussed earlier, can short-circuit much of this.
BCG Vaccine Safety and Side Effects
Parents from countries where BCG is routine rarely think twice about it, but the vaccine does carry some risk, which is part of why low-burden countries decline to use it. A prospective study of 100 BCG-vaccinated children found that 16 percent developed local reactions at the injection site, such as discharge, scarring, or abscess, sometimes with associated lymph node enlargement. Three children, all of whom turned out to be immunocompromised, developed disseminated BCG infection, a serious condition. The remaining 84 percent had self-limited or no complications.25PubMed Central. BCG related complications: A single center, prospective observational study A review of serious adverse events in China over a 12-year period found just 14 reported cases among the more than 300 million newborns vaccinated during that time, underscoring that serious harm is extremely rare in healthy infants.26PubMed Central. First vaccination after birth: serious adverse events of Bacillus Calmette-Guérin (BCG) in real-world The main risk group for severe BCG complications is children with undiagnosed immune deficiencies.
Newer Diagnostic Tools and Vaccines on the Horizon
The diagnostic landscape continues to evolve. A newer IGRA called LIOFeron includes an additional antigen that may help distinguish active TB from latent infection, a distinction that current tests handle poorly. In an evaluation of pediatric patients, this test showed extremely high accuracy for diagnosing TB infection and 100 percent sensitivity for detecting latent infection, outperforming the established QuantiFERON test, which had about 86 percent sensitivity for latent TB in the same study.27PubMed Central. Performance evaluation of the LIOFeron®TB/LTBI IGRA for screening of paediatric LTBI and tuberculosis If tests that reliably separate latent from active TB become widely available, school screening could become even more targeted and less disruptive.
On the vaccine front, the BCG vaccine is over a century old and researchers have been trying to replace or improve it for decades. The pediatric TB vaccine pipeline now includes novel whole-cell vaccines intended to replace BCG at birth and subunit vaccines designed as boosters during adolescence, when the original BCG protection has faded.28PubMed Central. What’s Old and New in Tuberculosis Vaccines for Children A more effective vaccine that did not interfere with diagnostic skin tests would change the global calculus entirely, potentially making universal vaccination practical even in low-burden countries. That prospect is still years away from clinical reality, but the pipeline is more active than it has been at any point in the past several decades.